646 related articles for article (PubMed ID: 23216382)
21. [Long-term pharmacological treatment of portal hypertension].
Brůha R; Petrtýl J; Urbánek P; Svestka T; Kaláb M; Marecek Z
Cas Lek Cesk; 2005; 144 Suppl 1():63-6. PubMed ID: 15981990
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
Irimia R; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
[TBL] [Abstract][Full Text] [Related]
23. [Complications of liver cirrhosis: portal hypertension, gastroesophageal varices and ascites].
Schuster MJ
Praxis (Bern 1994); 2003 Aug; 92(35):1427-34. PubMed ID: 14526628
[TBL] [Abstract][Full Text] [Related]
24. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
[TBL] [Abstract][Full Text] [Related]
25. Different patterns of decompensation in patients with alcoholic vs. non-alcoholic liver cirrhosis.
Wiegand J; Kühne M; Pradat P; Mössner J; Trepo C; Tillmann HL
Aliment Pharmacol Ther; 2012 Jun; 35(12):1443-50. PubMed ID: 22530565
[TBL] [Abstract][Full Text] [Related]
26. Infection as a Trigger for Portal Hypertension.
Steib CJ; Schewe J; Gerbes AL
Dig Dis; 2015; 33(4):570-6. PubMed ID: 26159275
[TBL] [Abstract][Full Text] [Related]
27. The portal hypertension syndrome: etiology, classification, relevance, and animal models.
Bosch J; Iwakiri Y
Hepatol Int; 2018 Feb; 12(Suppl 1):1-10. PubMed ID: 29064029
[TBL] [Abstract][Full Text] [Related]
28. Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome.
Ibrahim ES; Alsebaey A; Zaghla H; Moawad Abdelmageed S; Gameel K; Abdelsameea E
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1247-1250. PubMed ID: 28902040
[TBL] [Abstract][Full Text] [Related]
29. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis.
Elfert A; Abo Ali L; Soliman S; Ibrahim S; Abd-Elsalam S
Eur J Gastroenterol Hepatol; 2016 Dec; 28(12):1450-1454. PubMed ID: 27512927
[TBL] [Abstract][Full Text] [Related]
30. Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list.
Salehi S; Tranah TH; Lim S; Heaton N; Heneghan M; Aluvihare V; Patel VC; Shawcross DL
Aliment Pharmacol Ther; 2019 Aug; 50(4):435-441. PubMed ID: 31169941
[TBL] [Abstract][Full Text] [Related]
31. Complications of cirrhosis.
Mendez C; Marsano L; Wright R
J Ky Med Assoc; 2003 Sep; 101(9):403-14. PubMed ID: 14556436
[No Abstract] [Full Text] [Related]
32. Prognosis in patients with cirrhosis and mild portal hypertension.
Ytting H; Møller S; Henriksen JH; Larsen K; Bendtsen F
Scand J Gastroenterol; 2006 Dec; 41(12):1446-53. PubMed ID: 17101576
[TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
[TBL] [Abstract][Full Text] [Related]
34. [The long-term effect of molsidomine on frequency of hemorrhage, portal and cardiac hemodynamics in patients with liver cirrhosis--a pilot study].
Hüppe D; Jäger D; Tromm A; Barmeyer J; May B
Leber Magen Darm; 1993 May; 23(3):114-8, 121-2. PubMed ID: 8326815
[TBL] [Abstract][Full Text] [Related]
35. Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients.
Alvarez MA; Cirera I; Solà R; Bargalló A; Morillas RM; Planas R
J Clin Gastroenterol; 2011; 45(10):906-11. PubMed ID: 21814145
[TBL] [Abstract][Full Text] [Related]
36. [Current status and perspectives of diagnosis and treatment of complications related to liver cirrhosis].
Nan YM
Zhonghua Gan Zang Bing Za Zhi; 2017 Apr; 25(4):241-245. PubMed ID: 28494539
[TBL] [Abstract][Full Text] [Related]
37. Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: a retrospective study.
Castells A; Saló J; Planas R; Quer JC; Ginès A; Boix J; Ginès P; Gassull MA; Terés J; Arroyo V
Hepatology; 1994 Sep; 20(3):584-91. PubMed ID: 8076916
[TBL] [Abstract][Full Text] [Related]
38. Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis.
Dong T; Aronsohn A; Gautham Reddy K; Te HS
Dig Dis Sci; 2016 Dec; 61(12):3621-3626. PubMed ID: 27655104
[TBL] [Abstract][Full Text] [Related]
39. [A randomized placebo-controlled multicentre study of Fuzhenghuayu capsule for prevention of oesophageal variceal bleeding in patients with liver cirrhosis].
Xiao D; Gu J; Cai H; Zhang Q; Xue D; Zhao C; Xu L
Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):594-9. PubMed ID: 25243960
[TBL] [Abstract][Full Text] [Related]
40. [Rifaximin improves prognosis liver cirrhosis].
Füessl HS
MMW Fortschr Med; 2014 Aug; 156(14):35. PubMed ID: 25195402
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
